Balaxi Pharmaceuticals (BALAXI) Q1 26/27 earnings summary

Executive summary

• Approved unaudited standalone and consolidated financial results for the quarter ended 30th June 2026.

• Commenced commercial production at the new pharmaceutical formulation facility in Jadcherla, Hyderabad, with two initial products and permissions for 29 additional products, expanding the commercial portfolio to 31 products.

• WHO-GMP audit conducted at the new facility; CAPA response submitted and certification process underway.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was ₹8,068.18 lakhs, up from ₹7,071.37 lakhs in Q1 FY26.

• Consolidated net profit for Q1 FY27 stood at ₹129.74 lakhs, compared to ₹29.01 lakhs in Q1 FY26.

• Standalone revenue for Q1 FY27 was ₹1,558.37 lakhs, down from ₹1,670.82 lakhs in Q1 FY26.

• Standalone net loss for Q1 FY27 was ₹125.32 lakhs, compared to a net profit of ₹19.49 lakhs in Q1 FY26.

• Basic and diluted EPS for the consolidated entity was ₹0.24 for Q1 FY27, up from ₹0.05 in Q1 FY26.

Outlook and guidance

• Ongoing expansion of product portfolio and manufacturing operations at the new facility, with further product approvals being pursued.

• WHO-GMP certification expected to enhance manufacturing credentials and support future growth.